Santo

What Santo does

Polpharma Santo is the leading pharmaceutical manufacturer in Kazakhstan and a top player in Central Asia, operating as a subsidiary of the Poland-headquartered Polpharma Group. Its core business is the production and distribution of generic medicines, with a portfolio of more than 380 products spanning 14 pharmacotherapeutic groups, including treatments for type-2 diabetes, cardiovascular conditions, and pediatric care. Manufacturing is conducted at a GMP-certified facility on a 17-hectare site in Shymkent, equipped with state-of-the-art automated production lines from international OEMs, with a regional commercial office in Almaty.

The company's technology base is built on parent-group technology transfer, including access to Polpharma Group's Polish RNA technology platform, alongside integrated digital drug-marking and traceability capabilities aligned with Kazakhstan's national pharmaceutical regulatory framework. Distribution is conducted through pharmacy networks and government healthcare procurement channels in Kazakhstan, with active export to Uzbekistan and Kyrgyzstan tracked via IQVIA market data. The company also runs a clinical research program — most recently in type-2 diabetes — and engages healthcare professionals through a physician registration portal and dedicated adverse-event and quality-complaint channels.

Commercially, Polpharma Santo is part of a diversified international pharmaceutical conglomerate rather than a standalone Kazakh entity, with revenue and pricing mechanics not publicly disclosed. Its scale and positioning — market leader in Kazakhstan, largest pharma employer in the country, and a major private investor in domestic drug manufacturing — are reinforced by a 39.5 billion tenge capital commitment to expand Shymkent production and a 2025 leadership transition at the Polpharma Group level with a new Group President overseeing Central Asian operations.

Name

Santo

Legal name

Polpharma Santo

Website

https://santo.kz

Company type

Private

Founded year

1882

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Polpharma Santo is a Kazakhstan-based pharmaceutical manufacturer producing 380+ generic drugs across 14 therapeutic groups at a GMP-certified Shymkent facility, serving patients and healthcare providers in Kazakhstan, Uzbekistan, and Kyrgyzstan as a subsidiary of Poland's Polpharma Group.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

akta.pro secondary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Generic drug production
• Pharmaceutical distribution
• GMP-certified manufacturing

Headquarters

HQ city

Shymkent

HQ country

Kazakhstan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales

Distribution channels2 records

Marketing channels3 records

Core offering

Polpharma Santo manufactures and supplies a portfolio of more than 380 generic drugs spanning 14 pharmacotherapeutic groups at a GMP-certified facility in Shymkent, Kazakhstan. The company serves healthcare providers and patients in Kazakhstan and exports to Central Asian countries, and additionally offers pharmaceutical storage and transportation services supporting distribution.

Product overview

Polpharma Santo is a pharmaceutical company operating in Central Asian countries, specifically Kazakhstan, and is part of the international pharmaceutical Group Polpharma. The company offers a portfolio of more than 380 generic drugs across 14 pharmacotherapeutic groups for treating various diseases. The products are manufactured at GMP-certified facilities in Shymkent, Kazakhstan.

Differentiator

Problem solved

Functional benefit

Products and services

• Portfolio of generic pharmaceuticals (380+ drugs across 14 pharmacotherapeutic groups)
• Pharmaceutical storage and transportation services

Quantifiable outcome

• 39.5 billion tenge of private investment mobilized for production expansion in Shymkent

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• KRKA: KRKA is a Slovenian generic pharmaceutical manufacturer with a long-established presence in the CIS region, particularly Russia, Ukraine, and Central Asia. Its broad generic portfolio, vertical integration, and tender-driven business model closely mirror Santo's approach in Kazakhstan and neighboring markets.
• STADA Arzneimittel: STADA is a major European generics and consumer healthcare company with strong emerging-markets exposure, including CIS countries. Both companies compete on price, broad portfolio depth, and tenders in public procurement systems, making STADA a direct peer for benchmarking in regional generics.
• Pharmstandard: Pharmstandard is a leading Russian generic and OTC pharmaceutical manufacturer with a broad domestic portfolio and export presence across CIS markets including Kazakhstan. It competes directly with Santo for retail shelf space, government tenders, and chronic-disease categories such as diabetes and cardiovascular.
• R-Pharm: R-Pharm is a major Russian pharmaceutical manufacturer with strong CIS distribution, focused on generics, biotech, and contract manufacturing. It directly competes with Santo in Kazakhstan and Central Asian tenders with overlapping therapeutic categories.
• Polpharma Group: Polpharma Group is the Polish parent of Santo and one of the largest generic pharmaceutical manufacturers in Central and Eastern Europe with a similar generics-led portfolio, GMP manufacturing footprint, and CIS market presence. Santo effectively executes the same business model at Kazakhstan scale, making it directly comparable on strategy, manufacturing, and therapeutic coverage.
• Gedeon Richter: Gedeon Richter is a Hungarian-headquartered generic and specialty pharmaceutical company with deep historical penetration in CIS markets, including Russia, Ukraine, and Kazakhstan. Its combination of generic manufacturing and branded specialty products across multiple therapeutic areas maps closely to Santo's 14 pharmacotherapeutic group portfolio strategy.

Regional players

• Chimpharm (Chem-Pharm): Chimpharm is a domestic Kazakh pharmaceutical manufacturer of generics and infusion solutions and one of Santo's principal local competitors in the Kazakhstan market. It illustrates the home-player dynamic that Santo's localization advantage is built around.

Broad incumbents

• Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer, offering a global portfolio across nearly every therapeutic area. While operating at vastly greater scale and geographic breadth, Teva competes with Santo in selected generic categories and tenders within Central Asia and serves as the global benchmark for generics-led business models.
• Sandoz (Novartis): Sandoz, the generics and biosimilars arm of Novartis, is a global leader in off-patent medicines with growing presence in emerging markets. It provides a relevant benchmark for Santo in generics manufacturing scale, biosimilars pipeline thinking, and pricing dynamics in tenders where both compete.

Emerging players

• Nobel Pharma: Nobel (formerly Nobel İlaç) is a Turkish pharmaceutical manufacturer expanding across CIS and Central Asia with a generics portfolio that increasingly reaches Uzbek and Kazakh markets. Comparable to Santo as a regional generics challenger pursuing cross-border expansion into the same territories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Santo